newsfilter
← Latest News
GlobeNewswire·

Hemab Therapeutics Reports First Quarter 2026 Financial Results

COAG
  • Hemab Therapeutics completed an upsized Initial Public Offering in May 2026, raising $346.7 million in gross proceeds & listing on the Nasdaq Global Select Market under the ticker symbol "COAG".
  • The IPO consisted of 19,262,500 shares sold at $18.00 per share, including the full exercise of the underwriters' option to purchase an additional 2,512,500 shares.
  • The U.S. Food and Drug Administration granted Breakthrough Therapy Designation for sutacimig to treat Glanzmann thrombasthenia, recognizing the potential for substantial improvement over current standard of care.
  • Sutacimig also received Orphan Drug Designation from both the FDA & the European Medicines Agency for Glanzmann thrombasthenia.
  • The company anticipates initiating a Phase 3 pivotal clinical trial for sutacimig in Glanzmann thrombasthenia during the second half of 2026.
  • Sutacimig is currently being evaluated in an ongoing Phase 2 clinical trial for Factor VII deficiency, with data expected in late 2026 or early 2027.
  • HMB-002, a novel monovalent antibody for Von Willebrand Disease, is in an ongoing Phase 1/2 clinical trial with data expected in late 2026 or early 2027.
  • As of March 31, 2026, cash, cash equivalents, & marketable securities totaled $163.5 million, with net IPO proceeds of approximately $317.2 million expected to fund operations into 2029.
  • Research and development expenses for the first quarter of 2026 were $19.5 million, compared to $14.1 million in the same period of 2025.
  • General and administrative expenses for the first quarter of 2026 were $4.2 million, compared to $2.5 million in the same period of 2025.
  • The company reported a net loss of $22.7 million for the three months ended March 31, 2026, equating to $23.98 per share, compared to a net loss of $15.3 million in the prior year period.